{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:31Z","timestamp":1787019631876,"version":"build-2736575974"},"reference-count":32,"publisher":"European Respiratory Society (ERS)","issue":"6","license":[{"start":{"date-parts":[[2022,7,26]],"date-time":"2022-07-26T00:00:00Z","timestamp":1658793600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["publications.ersnet.org"],"crossmark-restriction":true},"short-container-title":["Eur Respir J"],"accepted":{"date-parts":[[2022,7,4]]},"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Oral corticosteroid (OCS) dependence among patients with severe eosinophilic asthma can cause adverse outcomes, including adrenal insufficiency. PONENTE's OCS reduction phase showed that, following benralizumab initiation, 91.5% of patients eliminated corticosteroids or achieved a final dosage \u22645\u2005mg\u00b7day\n                      <jats:sup>\u22121<\/jats:sup>\n                      (median (range) 0.0 (0.0\u201340.0)\u2005mg).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The maintenance phase assessed the durability of corticosteroid reduction and further adrenal function recovery. For \u223c6\u2005months, patients continued benralizumab 30\u2005mg every 8\u2005weeks without corticosteroids or with the final dosage achieved during the reduction phase. Investigators could prescribe corticosteroids for asthma exacerbations or increase daily dosages for asthma control deteriorations. Outcomes included changes in daily OCS dosage, Asthma Control Questionnaire (ACQ)-6 and St George's Respiratory Questionnaire (SGRQ), as well as adrenal status, asthma exacerbations and adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>598 patients entered PONENTE; 563 (94.1%) completed the reduction phase and entered the maintenance phase. From the end of reduction to the end of maintenance, the median (range) OCS dosage was unchanged (0.0 (0.0\u201340.0)\u2005mg), 3.2% (n=18\/563) of patients experienced daily dosage increases, the mean ACQ-6 score decreased from 1.26 to 1.18 and 84.5% (n=476\/563) of patients were exacerbation free. The mean SGRQ improvement (\u201319.65\u2005points) from baseline to the end of maintenance indicated substantial quality-of-life improvements. Of patients entering the maintenance phase with adrenal insufficiency, 32.4% (n=104\/321) demonstrated an improvement in adrenal function. Adverse events were consistent with previous reports.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Most patients successfully maintained maximal OCS reduction while achieving improved asthma control with few exacerbations and maintaining or recovering adrenal function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1183\/13993003.03226-2021","type":"journal-article","created":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T01:45:11Z","timestamp":1658972711000},"page":"2103226","update-policy":"https:\/\/doi.org\/10.1183\/ers-crossmark-policy","source":"Crossref","is-referenced-by-count":17,"title":["Adrenal function recovery after durable oral corticosteroid sparing with benralizumab in the PONENTE study"],"prefix":"10.1183","volume":"60","author":[{"given":"Andrew","family":"Menzies-Gow","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Gurnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam G.","family":"Heaney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Corren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth H.","family":"Bel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge","family":"Maspero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Njira","family":"Lugogo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kreindler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Burden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"de Giorgio-Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarai","family":"Faison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0089-7677","authenticated-orcid":false,"given":"Ubaldo J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Garcia Gil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PONENTE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"81","published-online":{"date-parts":[[2022,7,26]]},"reference":[{"key":"2024102103030088000_60.6.2103226.1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1164\/rccm.201904-0903SO","article-title":"Systematic literature review of systemic corticosteroid use for asthma management","volume":"201","author":"Bleecker","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2024102103030088000_60.6.2103226.2","doi-asserted-by":"publisher","DOI":"10.1111\/all.13556"},{"key":"2024102103030088000_60.6.2103226.3","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.chest.2019.10.053","article-title":"Characterization of severe asthma worldwide: data from the International Severe Asthma Registry","volume":"157","author":"Wang","year":"2020","journal-title":"Chest"},{"key":"2024102103030088000_60.6.2103226.4","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00202013"},{"key":"2024102103030088000_60.6.2103226.5","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/resp.13730","article-title":"Rational oral corticosteroid use in adult severe asthma: a narrative review","volume":"25","author":"Chung","year":"2020","journal-title":"Respirology"},{"key":"2024102103030088000_60.6.2103226.6","unstructured":"Global Initiative for Asthma (GINA) . Global Strategy for Asthma Management and Prevention. 2021. Available from: https:\/\/ginasthma.org\/"},{"key":"2024102103030088000_60.6.2103226.7","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1218"},{"key":"2024102103030088000_60.6.2103226.8","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02273-2019"},{"key":"2024102103030088000_60.6.2103226.9","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18102201"},{"key":"2024102103030088000_60.6.2103226.10","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N Engl J Med"},{"key":"2024102103030088000_60.6.2103226.11","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2024102103030088000_60.6.2103226.12","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00009-2019"},{"key":"2024102103030088000_60.6.2103226.13","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S2213-2600(21)00352-0","article-title":"Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study","volume":"10","author":"Menzies-Gow","year":"2022","journal-title":"Lancet Respir Med"},{"key":"2024102103030088000_60.6.2103226.14","doi-asserted-by":"publisher","DOI":"10.1177\/0004563213509793"},{"key":"2024102103030088000_60.6.2103226.15","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-1700"},{"key":"2024102103030088000_60.6.2103226.16","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1210\/jc.2018-00529","article-title":"The short synacten (corticotropin) test can be used to predict recovery of hypothalamo-pituitary-adrenal axis function","volume":"103","author":"Pofi","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"key":"2024102103030088000_60.6.2103226.17","unstructured":"Society for Endocrinology . Society position statements: use of synthetic ACTH (Synacthen) in patients with a history of asthma. 2020. www.endocrinology.org\/clinical-practice\/clinical-guidance\/society-position-statements\/ Date last accessed: 11 February 2022."},{"key":"2024102103030088000_60.6.2103226.18","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1530\/EJE-20-1199","article-title":"Management of endocrine disease: glucocorticoid-induced adrenal insufficiency: replace while we wait for evidence?","volume":"184","author":"Laugesen","year":"2021","journal-title":"Eur J Endocrinol"},{"key":"2024102103030088000_60.6.2103226.19","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3904\/kjim.2019.198","article-title":"Efficacy and safety of mepolizumab in Korean patients with severe eosinophilic asthma from the DREAM and MENSA studies","volume":"36","author":"Kim","year":"2021","journal-title":"Korean J Intern Med"},{"key":"2024102103030088000_60.6.2103226.20","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2147\/JAA.S240044","article-title":"Onset of effect, changes in airflow obstruction and lung volume, and health-related quality of life improvements with benralizumab for patients with severe eosinophilic asthma: phase IIIb randomized, controlled trial (SOLANA)","volume":"13","author":"Panettieri","year":"2020","journal-title":"J Asthma Allergy"},{"key":"2024102103030088000_60.6.2103226.21","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s41687-021-00338-6","article-title":"Measuring respiratory symptoms in moderate\/severe asthma: evaluation of a respiratory symptom tool, the ER-S: COPD in asthma populations","volume":"5","author":"Tabberer","year":"2021","journal-title":"J Patient Rep Outcomes"},{"key":"2024102103030088000_60.6.2103226.22","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.02.00063702"},{"key":"2024102103030088000_60.6.2103226.23","doi-asserted-by":"publisher","DOI":"10.1530\/EC-16-0054"},{"key":"2024102103030088000_60.6.2103226.24","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00100-2015"},{"key":"2024102103030088000_60.6.2103226.25","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00024-2015"},{"key":"2024102103030088000_60.6.2103226.26","doi-asserted-by":"crossref","first-page":"21152127","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting \u03b22-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"key":"2024102103030088000_60.6.2103226.27","doi-asserted-by":"crossref","first-page":"21282141","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"key":"2024102103030088000_60.6.2103226.28","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/S2213-2600(20)30414-8","article-title":"Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial","volume":"9","author":"Harrison","year":"2021","journal-title":"Lancet Respir Med"},{"key":"2024102103030088000_60.6.2103226.29","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1080\/02770903.2019.1630640","article-title":"Impact of exacerbations on St George's Respiratory Questionnaire score in patients with severe asthma: post hoc analyses of two clinical trials and an observational study","volume":"57","author":"Nelson","year":"2020","journal-title":"J Asthma"},{"key":"2024102103030088000_60.6.2103226.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.08.2083"},{"key":"2024102103030088000_60.6.2103226.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2020.03.042"},{"key":"2024102103030088000_60.6.2103226.32","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/joim.13273","article-title":"Long-term corticosteroid use, adrenal insufficiency and the need for steroid-sparing treatment in adult severe asthma","volume":"290","author":"Gurnell","year":"2021","journal-title":"J Intern Med"}],"container-title":["European Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1183\/13993003.03226-2021","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T02:08:15Z","timestamp":1740362895000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.ersnet.org\/lookup\/doi\/10.1183\/13993003.03226-2021"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,26]]},"references-count":32,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,12,22]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.1183\/13993003.03226-2021"],"URL":"https:\/\/doi.org\/10.1183\/13993003.03226-2021","relation":{},"ISSN":["0903-1936","1399-3003"],"issn-type":[{"value":"0903-1936","type":"print"},{"value":"1399-3003","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,26]]}}}